Drug Profile
Research programme: neuronal nitric oxide synthase inhibitors - AstraZeneca
Alternative Names: Neuronal nitric oxide synthase inhibitors research programme - AstraZenecaLatest Information Update: 24 Aug 2006
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Nitric oxide synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 24 Aug 2006 Discontinued - Preclinical for Parkinson's disease in Sweden (unspecified route)
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
- 11 Feb 1998 New profile